Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.62 |
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.42 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.41 |
| ▸ | PGK1 | P00558 | 1/20 | 0.40 |
| ▸ | PGK2 | P07205 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CBLB | Q13191 | 8/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29709918 | 1.00 | P2RX7 (0.62) | P2RX7AHRTAS2R14DDR1IRAK4 | |
| SCHEMBL27737055 | 0.86 | P2RX7 (0.68) | P2RX7AHRTAS2R14DDR1IRAK4 | |
| SCHEMBL22836421 | 0.85 | P2RX7 (0.46) | P2RX7AHRDDR1IRAK4PGK1 | |
| SCHEMBL22835284 | 0.85 | P2RX7 (0.46) | P2RX7AHRDDR1IRAK4PGK1 | |
| SCHEMBL29375278 | 0.82 | P2RX7 (0.64) | P2RX7AHRTAS2R14IRAK4PGK1 | |
| SCHEMBL28015459 | 0.82 | P2RX7 (0.64) | P2RX7AHRTAS2R14DDR1IRAK4 | |
| SCHEMBL496206 | 0.82 | P2RX7 (0.64) | P2RX7AHRTAS2R14IRAK4PGK1 | |
| SCHEMBL2826285 | 0.81 | P2RX7 (0.67) | P2RX7AHRTAS2R14IRAK4PGK1 | |
| SCHEMBL29799817 | 0.81 | P2RX7 (0.62) | P2RX7AHRTAS2R14DDR1IRAK4 | |
| SCHEMBL13043982 | 0.81 | P2RX7 (0.62) | P2RX7AHRTAS2R14DDR1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107382989-A | A kind of synthetic method with oxazole ring structure immunosuppressive drug | 河南科技大学第附属医院 | 2017-11-24 | — | — | CN | claimed |
| CN-107298677-A | The preparation method and application of evil azole compounds with immunosuppressive activity | 侯茜茜 | 2017-10-27 | — | — | CN | claimed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12539295-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250375526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250333417-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250214972-A1 | FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2025-07-03 | — | — | US | disclosed |
| US-12281098-B2 | Five-membered-fused six-membered compound, preparation method, pharmaceutical composition and use | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2025-04-22 | — | — | US | disclosed |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12150995-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20140378686-A1 | Indanyl-Substituted 4,5,6,7-Tetrahydro-1H-Pyrazolo[4,3-C]Pyridines, Their Use as Medicament, and Pharmaceutical Preparations Comprising Them | SANOFI (FR) | 2014-12-25 | — | — | US | disclosed |
| US-8901145-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140330009-A1 | Substituted 4,5,6,7-Tetrahydro-1H-Pyrazolo[4,3-C]Pyridines, Their Use as Medicament, and Pharmaceutical Preparations Comprising Them | SANOFI (FR) | 2014-11-06 | — | — | US | disclosed |
| EP-2699569-A2 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals LLC (US) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012145617-A9 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals, LLC (US) | 2014-02-20 | — | — | WO | disclosed |
| WO-2013190508-A2 | 1-[M-CARBOXAMIDO(HETERO)ARYL-METHYL]-HETEROCYCLYL-CARBOXAMIDE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-12-27 | — | — | WO | disclosed |
| US-20130345199-A1 | 1-[M-CARBOXAMIDO(HETERO)ARYL-METHYL]-PIPERIDINE-4-CARBOXAMIDE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-26 | — | — | US | disclosed |
| WO-2012145617-A2 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals, LLC (US) | 2012-10-26 | — | — | WO | disclosed |
| US-20120270892-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | P2RX7 3982/4885AHR 885/4885TAS2R14 2137/4885 |
| US-12281098-B2 | Five-membered-fused six-membered compound, preparation method, pharmaceutical composition and use | IRAK4, IRAK2, TRAF6 | P2RX7 1212/4885AHR 1343/4885TAS2R14 2651/4885 |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | P2RX7 1103/4885AHR 327/4885TAS2R14 3823/4885 |
| US-20250375526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | P2RX7 1103/4885AHR 327/4885TAS2R14 3823/4885 |
| US-12539295-B2 | IRAK degraders and uses thereof | IRAK2, IRAK4, IRAK3 | P2RX7 1652/4885AHR 195/4885TAS2R14 1805/4885 |
| US-12150995-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | P2RX7 1103/4885AHR 327/4885TAS2R14 3823/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | P2RX7 1935/4885AHR 342/4885TAS2R14 1659/4885 |
| US-20120270892-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | P2RX7 4053/4885AHR 2428/4885TAS2R14 4454/4885 |
| US-20140378686-A1 | Indanyl-Substituted 4,5,6,7-Tetrahydro-1H-Pyrazolo[4,3-C]Pyridines, Their Use as Medicament, and Pharmaceutical Preparations Comprising Them | KCNA1, KCNT1, CACNA1G | P2RX7 268/4885AHR 1010/4885TAS2R14 2288/4885 |
| US-20250333417-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | P2RX7 1103/4885AHR 327/4885TAS2R14 3823/4885 |
| US-20130345199-A1 | 1-[M-CARBOXAMIDO(HETERO)ARYL-METHYL]-PIPERIDINE-4-CARBOXAMIDE DERIVATIVES | CXCR1, CXCR5, CXCR4 | P2RX7 8/4885AHR 427/4885TAS2R14 684/4885 |
| US-20250214972-A1 | FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | IRAK4, IRAK2, TRAF6 | P2RX7 1212/4885AHR 1343/4885TAS2R14 2651/4885 |
| US-20140330009-A1 | Substituted 4,5,6,7-Tetrahydro-1H-Pyrazolo[4,3-C]Pyridines, Their Use as Medicament, and Pharmaceutical Preparations Comprising Them | KCNA1, KCNT1, KCNJ11 | P2RX7 187/4885AHR 919/4885TAS2R14 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.